Media

THE PHARMA LETTER: USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors.

BIOSPACE: Building stronger companies requires the right leadership. This week, life sciences companies from across the globe pinpoint the Movers & Shakers who will best benefit their company.

BioRxIV, Drakes, et. al.

Presentation — Keystone Emerging Cellular Therapies Conference 2022, Dylan Drakes, PhD

Presentation — Vaccine Summit Boston 2022, Pete DeMuth, PhD

Presentation — STING & TLR — Targeting Therapies Summit 2022, Pete DeMuth, PhD

PHARMA’S ALMANAC: 2022 Milestones

PHARMA’S ALMANAC: Progress in Therapeutics

SCRIP: High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease

BIOSPACE: We picked the brains of 10 biotech CEOs and founders to solicit their advice for first-time founders. Here’s what they told us: